Guangli Biotechnology Holdings Co., Ltd. 2025 Q4 Financial Report
NQ Score
53/100
N1 Content Completeness
3
AI Summary (NQ-processed)
Guangli Biotechnology Holdings Co., Ltd. reported an operating revenue of 377 million NTD and a net loss after tax of 193 million NTD for Q4 2025, resulting in a basic EPS of -2.07 NTD.
AI analysis data is not yet available.